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Loss of BRCC3 Deubiquitinating Enzyme
Leads to Abnormal Angiogenesis
and Is Associated with Syndromic Moyamoya
Snaigune Miskinyte,1,10 Matthew G. Butler,2,10 Dominique Herve´,3,10 Catherine Sarret,4 Marc Nicolino,5
Jacob D. Petralia,6 Francoise Bergametti,1 Minh Arnould,1 Van N. Pham,2 Aniket V. Gore,2
Konstantinos Spengos,7 Steven Gazal,8 France Woimant,3 Gary K. Steinberg,6 Brant M. Weinstein,2
and Elisabeth Tournier-Lasserve1,9,*
Moyamoya is a cerebrovascular angiopathy characterized by a progressive stenosis of the terminal part of the intracranial carotid arteries
and the compensatory development of abnormal and fragile collateral vessels, also called moyamoya vessels, leading to ischemic and
hemorrhagic stroke. Moyamoya angiopathy can either be the sole manifestation of the disease (moyamoya disease) or be associated
with various conditions, including neurofibromatosis, Down syndrome, TAAD (autosomal-dominant thoracic aortic aneurysm), and
radiotherapy of head tumors (moyamoya syndromes). Its prevalence is ten times higher in Japan than in Europe, and an estimated
6%–12% of moyamoya disease is familial in Japan. The pathophysiological mechanisms of this condition remain obscure. Here, we
report on three unrelated families affected with an X-linked moyamoya syndrome characterized by the association of a moyamoya
angiopathy, short stature, and a stereotyped facial dysmorphism. Other symptoms include an hypergonadotropic hypogonadism,
hypertension, dilated cardiomyopathy, premature coronary heart disease, premature hair graying, and early bilateral acquired cataract.
We show that this syndromic moyamoya is caused by Xq28 deletions removingMTCP1/MTCP1NB and BRCC3. We also show that brcc3
morphant zebrafish display angiogenesis defects that are rescued by endothelium-specific expression of brcc3. Altogether, these data
strongly suggest that BRCC3, a deubiquitinating enzyme that is part of the cellular BRCA1 and BRISC complexes, is an important player
in angiogenesis and that BRCC3 loss-of-function mutations are associated with moyamoya angiopathy.Introduction
Moyamoya (MIM 252350, MIM 607151, MIM 608796) is
a cerebrovascular angiopathy characterizedby a progressive
stenosis of the terminal part of the intracranial internal
carotid arteries (ICA) and their proximal branches within
the circle of Willis.1,2 This disease is associated with the
compensatory development of abnormal, thin, and fragile
collateral vessels (‘‘moyamoya’’ vessels) at the base of the
brain. Reduced cerebral blood flow and rupture of the
fragile collateral vessels cause ischemic and hemorrhagic
stroke in children and adults with moyamoya. The preva-
lence of this disorder has been estimated to be close to
3/100 000 in Japan and is ten times less prevalent in
Europe.1,2
Histopathological analysis of affected carotids shows a
marked decrease in the outer diameters of the carotid
terminations, a fibrocellular thickening of the intima con-
taining proliferating smooth-muscle actin-positive cells,
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elastic lamina, thinned media in the vessel wall, and mi-
croaneurysms.3 Despite a great deal of investigation, the
molecular etiology and pathogenesis of moyamoya angi-
opathy remains unclear.4
Moyamoya angiopathy can be associated with different
conditions, including tuberculous meningitis, atheroscle-
rosis, radiotherapy of head tumors, and various diseases
of known genetic etiology, such as Down syndrome
(MIM 190685), neurofibromatosis type 1 (MIM 162200),
sickle cell disease (MIM 603903), and autosomal-dominant
thoracic aortic aneurysm disease, also called TAAD (MIM
102620).1,5–7 These conditions are known as moyamoya
syndromes. They are distinct from moyamoya disease
(MMD), which occurs as an idiopathic disorder in which
the sole manifestation of the disease is the moyamoya
angiopathy.
MMD occurs predominantly in patients of Asian origin,
and the highest prevalence of the disease is found in Japan,
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Figure 1. Genealogical Trees of Families F1, F2, and F3
Circles: females. Squares: males. Black-filled symbols: affected
individuals. Empty symbols: healthy individuals. Members whose
blood has been sampled are indicated by an asterisk.in people of all ethnicities and in all age groups. Although
most cases of MMD appear to be sporadic, an estimated
6% 12% of all reported cases in Japan are familial. The
inheritance has been suggested to follow an autosomal-
dominant, autosomal-recessive, X-linked-recessive, or
multifactorial inheritance pattern.8 Several whole-genome
linkage studies have been aimed at identification of MMD
genetic loci. Linkage analyses conducted in Japanese fami-
lies suggested that MMD candidate loci might be located
at 3p24.2-p26, 6q25, 8q23, 12p12, and 17q25.9–12 No
mutated gene has yet been identified within those linked
regions. Interestingly, a recent genome-wide association
study suggested that RNF213 (MIM 613768), a gene that
is located at 17q25 and encodes a ring finger protein, is
an MMD susceptibility gene.13 Additionally, mutations in
ACTA2 (MIM 102620), which encodes the vascular
smooth-muscle-cell-specific isoform of a-actin, have been
reported in rare MMD patients.14
Herein, we report on three unrelated families affected by
an X-linked moyamoya syndrome in which an overlap-
ping deletion at Xq28 removes MTCP1/MTCP1NB (MIM
300116) and BRCC3 (MIM 300617) and cosegregates
with the affected phenotype. Morpholino-mediated
knockdown of the BRCC3 ortholog in zebrafish led toThe Amedefective angiogenesis that was rescued by endothelial-
specific expression of brcc3, strongly suggesting that this
deubiquitinating enzyme is a novel important player in
angiogenesis.Material and Methods
Patients and Families
Three families (F1–F3) including a total of ten males affected by a
syndromic moyamoya condition were included in this study. All
patients and family members provided written informed consent.
This study was conducted in accordance with ethical recommen-
dations in France for genetic disorders. The geneological trees
are shown in Figure 1. Some of the clinical and magnetic reso-
nance imaging (MRI) features of family F1 have previously been
reported.6 Additional information on family F1 as well as clinical,
biological, and MRI features of F2 family members and of two of
the affected F3 family members is provided in the results section.
Three additional unrelated families including two offspring
showing pure, nonsyndromic MMD were also included in this
study (F4: two brothers. F5: brother and sister. F6: two sisters).
DNA and RNA Extraction
Genomic DNA from probands and consenting relatives was
extracted from peripheral blood leukocytes by standard proce-
dures. F1–F3 family members whose blood was sampled are indi-
cated in Figure 1. Total RNA was isolated from lymphoblastoid
Epstein-Barr virus (EBV) cell lines via the Trizol method and tran-
scribed into cDNA via dT primers. RNA was available for probands
of families F1, F2, F4, and F5.
Microsatellite Markers and Chromosome X
Haplotyping
Family F1 was genotyped with a panel of 19 microsatellite markers
spanning the X chromosome (average genetic distance ¼ 20 cM).
Additional microsatellite markers, DXS984, DXS8106, DXS8045,
DXS1193, and DXS8061, were used for Xq27-q28 haplotyping
in family F1. Parametric multipoint and two-point linkage anal-
yses were carried out with the MINX program of MERLIN v1.1.2
package; a recessive X-linked model with complete penetrance,
disease allele frequency of 0.0001, and a phenocopy frequency
of 0.0001 were assumed.
Copy-Number Analysis with Affymetrix SNP 6.0
Arrays
On the basis of the hypothesis that a deletionmight be involved in
the disease mechanisms, we used high-density Affymetrix SNP 6.0
arrays (Affymetrix Santa Clara, CA) to search for putative deletions
located within the linked region on the X chromosome in family
F1. Genomic DNA from themother (F1 I-2) and two of her affected
sons (F1 II-3 and F1 II-4) was used for genotyping and copy-
number analysis. Sample processing and labeling were performed
according to the manufacturer’s instructions (Affymetrix Cytoge-
netics Copy Number Assay User Guide, P/N 702607 Rev. 2).
Hybridization was performed with a GeneChip Hybridization
oven 640 at 50C and 60 rpm for 16 hr, washed with a GeneChip
Fluidics Station 450, and scanned with a GeneChip Scanner
3000-7G. The image data were processed with the Affymetrix
Genotyping Console (GTC v4.0) for determination of SNP call
and copy-number variation.rican Journal of Human Genetics 88, 718–728, June 10, 2011 719
UCSC databases, the HapMap project, and the Database of
Genomic Variants were used for filtering copy-number polymor-
phisms within the region of interest.
STS Markers and Oligonucleotides Used for Walking
PCR
To confirm the putative deletion in family F1 and refine the critical
interval, we used a panel of 12 STS markers selected from NCBI
build 36.3 or designed with Primer 3 software (Table S1, available
online). Two of these STS markers, ECD13623 and ECD22603,
closely flanked the putative deletion. Three of these STS markers
(ECD07678, ECD07752, and ECD15347) map within FUNDC2,
MTCP1/MTCP1NB, and BRCC3. Standard PCR was carried out
with DNA from all affected males, two obligatory female carriers
(F1 I-2 and F1 II-5), and healthy males (F1 III-2 and F1 III-3). Addi-
tional oligonucleotides were used for walking PCR in family F2
(Table S1).
Long-Range PCR and Sequencing
In order to identify the deletion breakpoints, we performed long-
range PCR with primers ECD21451 (forward) and ECD02005R
(reverse) in family F1 and STSR7 (forward) and BRCC3R4 (reverse)
in families F2 and F3 (Table S1 and S2). Long-range PCR was
carried out on DNA from all affected individuals and each obliga-
tory carrier female. Unaffected spouses were included as negative
controls. The reactions were carried out with the Expand
20 kbPLUS PCR system (Roche) according to the manufacturer’s
instructions. Purified PCR products were sequenced with BigDye
Terminator 3.1 (Applied Biosystems, Foster City, CA) chemistry
on an ABI 3130 DNA sequencing apparatus according to the
manufacturer’s instructions.
Screening for BRCC3 and MTCP1/MTCP1NB
in Familial MMD Cases
All coding exons and flanking splice sites of BRCC3, MTCP1, and
MTCP1NB were amplified and sequenced with the genomic DNA
of probands from families F4–F6 (RefSeq accession numbers:
BRCC3, NM_001018055.1; MTCP1, NM_001018025.3; and
MTCP1NB, NM_001018024.2) . Sequencing primers are shown
in Table S2.
Immunoblot Analyses
A polyclonal antibody specific for human BRCC3 was purchased
from ProSci (reference number 4331F). A polyclonal antibody
specific for human p8MTCP1NB was kindly provided by M.H. Stern
(Institut Curie, France).
Immunoblot analysis of p8MTCP1NB and BRCC3 expression in
EBV-transformed lymphoblastoid cell lines from patients F1 II-2
and F2 II-2 and two healthy controls was conducted with 10 mg
of total protein lysates.
In addition, 10 mg of protein lysates from HUVEC endothelial
cells, 40 mg of total protein from human adult arterial tissue (Gen-
taurMolecular Products P1234013), and total protein fromhuman
adult vein tissue (Gentaur Molecular Products P1234020) were
used in screens for p8MTCP1NB and BRCC3 protein levels.
Zebrafish Lines and Husbandry
EK strain wild-type fish were used for in situ hybridization, and
both Tg(fli1-eGFP)y1 and Tg(flk1a-eGFP) were used in morpholino
knockdown experiments.15 All lines were maintained according
to established convention.16720 The American Journal of Human Genetics 88, 718–728, June 10,brcc3 and mtcp1nb cDNA Cloning and In Situ
Hybridization
Total RNA was isolated from 24 hpf wild-type zebrafish embryos
with TRIzol (Invitrogen, Carlsbad, CA) and reversed transcribed
with the SuperScript III First Strand Synthesis System (Invitrogen).
brcc3 andmtcp1nb cDNAs were amplified from cDNA by PCR with
the following primers:
brcc3-F: 50-TTCGCGATGGCTGTCAACGCGGTGCATTT-30
brcc3-R: 50-TTACAATGCCGCCAGCTCTTGCGTCAGC-30
mtcp1nb-F: 50-AGCTCGAAGTCGGAGTTCATTTC-30
mtcp1nb-R: 50-GACAGTGTTTAATGATGTGTAGCAGCA-30
The resultingPCRproductswerecloned intopCRII-TOPO (In-
vitrogen) according to manufacturer’s protocol. Riboprobes were
generated using the mMESSAGE mMACHINE T7 Kit (Life Tech-
nologies Corp., Carlsbad, CA). Riboprobes were generated with
the Roche DIG RNA Labeling Kit (Indianapolis, IN). Whole-mount
in situ hybridization was performed as previously described.17
Morpholino, mRNA, and DNA Injections
Morpholinos were designed to disrupt splicing of brcc3 ormtcp1nb
(Gene Tools, LLC. Philomath, OR). The brcc3 morpholino
(50-GTGATGCAGGAATAAAGCACATTCA-30) or mtcp1nb morpho-
lino (50-AGCTGATAAACACAAAAGTCACACA-30) was injected
into one-cell-stage Tg(fli1-eGFP)y1 or Tg(flk1a-eGFP) embryos. The
effectiveness of the brcc3morpholino was verified by reverse tran-
scriptase PCR (RT-PCR) aimed at detecting loss of the appropriately
spliced gene product (data not shown). The brcc3 and mtcp1nb
morpholinos were injected at doses of 9.5 pg and 4.0 pg, respec-
tively. For mRNA rescue experiments, wild-type brcc3 was cloned
into pCS-DEST and transcribed with the Ambion mMESSAGE
mMACHINE SP6 Kit. brcc3 was injected (375 pg) into control or
brcc3 morpholino-injected embryos.18 Injection of brcc3 mRNA
into control animals had no effect on vessel growth (data not
shown). Endothelium-specific rescue of brcc3 morphants was per-
formed by mosaic expression of brcc3 via a 6.4 kb flk1 promoter.19
Detailed methods for construction of flk1-mCherry-2A-brcc3 and
flk1-mCherry transgenes are provided in Figure S5. SceI homing
endonuclease was coinjected with the mcherry-2a-brcc3 transgene
(30 pg) so that mosaicism would be increased.20
Microscopy and Imaging
The vascular endothelium of injected Tg(fli1-eGFP)y1 and
Tg(flk-eGFP) was illuminated with a 488 nm argon laser and visu-
alized with an Olympus BX61WI confocal microscope. Embryos
were mounted laterally in Nusieve GTG agarose (0.5% in Embryo
water), and optical sections were collected through the trunk at
1.5 mm intervals. Confocal Z series were rendered into three-
dimensional representations with Olympus Fluoview software.
For quantitation of phenotypes, ten ISVs from each of 12 different
injected embryos were scored for each control and experimental
condition. Statistical significance was determined by a two-sided
student’s t test calculation at a 99.9% confidence interval.Results
Clinical Features of Families F1–F3
Within families F1 and F2, a total of seven males showed
a strikingly similar phenotype characterized by the2011
Figure 2. Facial Dysmorphy and Moyamoya Angiopathy of
Cases F1 II-2, F1 III-1, and F2 II-2
(A) facial dysmorphy observed in three affected members from
families F1 and F2. Hypertelorism is obvious in F1 III-1 and F2
II-2, and a long philtrum is observed in all three patients. Prema-
ture white hair locks are present in F1 II-2 and F1 III-1 (note that
F1 III-1 dyed his hair).
(B and C) Moyamoya angiopathy. In case F2 II-2, conventional
angiography showed an occlusion of a distal internal carotid artery
(purple arrow), and MRI revealed neovascularization (yellow
arrows) associated with bilateral small deep infarcts (red arrows).
Magnetic resonance angiography (MRA) of case F1 II-2 showed
a stenosis of the terminal portion of the internal carotid arteries
and of the origin of anterior andmiddle cerebral arteries associated
with a left cortical infarct on FLAIR images (red arrow). Cerebral
MRA and MRI did not detect any moyamoya angiopathy nor
parenchymal lesion in F1 III-1, the youngest patient of family F1.association of a moyamoya angiopathy, a hypergonado-
tropic hypogonadism, and several multisystemic manifes-
tations (Figure 1 and Figure 2). The main clinical, biolog-
ical, and morphological features of this condition are
summarized in Table 1.
In family 1, five male members related through a
maternal lineage over two generations were clinically
symptomatic, strongly suggesting an X-linked pattern of
inheritance. Moyamoya angiopathy was responsible for
cerebral infarcts or hemorrhages in four of these affected
individuals, and the age of individuals at onset of acute
neurological symptoms ranged from 4 to 32 years. A
progressive worsening of arterial narrowing associated
with additional strokes was observed in two affected
members, F1 II-1 and F1 II-2, (Figure 3). One member (F1
III-1) had no intracranial artery abnormality, but he wasThe Ameonly 27 years at the time of the last examination. Short
stature of postnatal onset was constant and associated
with azoospermia at adulthood. All patients had increased
levels of gonadotropic hormones as a result of a primary
gonadal failure. GH deficiency was partial when observed
and was never associated with any pituitary gland abnor-
mality detectable by MRI. Another hallmark observed in
all affectedmembers was a stereotyped facial dysmorphism
with hypertelorism, long philtrum, mild ptosis, and
premature white hair locks. The hands were small and
had short and broad fingers. Involvement of the heart
varied from isolated and asymptomatic left ventricular
enlargement to severe nonspecific dilated cardiomyopathy
responsible for heart failure and recurrent neurologic defi-
cits due to low cardiac output. Other manifestations of the
disease in this family included a right aortic arch in one
affected individual and a nonspecific bilateral early-onset
cataract in four affected individuals. High-resolution kar-
yotyping performed for four of the patients was normal.
In family 2, two male siblings born from nonconsangui-
neous healthy parents with unremarkable family, prenatal,
and perinatal histories were affected (Figure 1, Table 1).
At the age of 12 years, they were both diagnosed with
short stature and delayed puberty. Biologically, the results
suggested a partial deficiency of growth hormone and
a hypergonadotropic hypogonadism with preferential
dysfunction of Sertoli cells (Table 1). Neither pituitary
gland nor brain abnormalities were observed on a cerebral
MRI scan. Case F2 II-1 received a substitutive therapy by
rhGH from age 13. The growth rate remained low despite
a high dose of rhGH (55 mg/kg/day). At age 17, the delayed
puberty resolved progressively during treatment. He never
had neurological symptoms, but cerebral MRI detected
a moyamoya angiopathy with severe stenosis of the
terminal portion of ICAs. Case F2 II-2 suffered from dys-
praxia during childhood. At age 14, he had a diagnostic
work-up prior to rhGH treatment. Imaging of the brain
revealed a moyamoya angiopathy with occlusion of both
distal ICA and an extensive neovascularization in the terri-
tory of lenticulostriate arteries. Arterial hypertension was
suspected and confirmed by blood-pressure monitoring.
Ultrasound examination excluded stenosis of the renal
arteries. In both siblings, hypertelorism, mild bilateral
ptosis, long philtrum, and flared nares were observed.
Neither cataract nor dilated cardiomyopathy were present
at the last examination (when the siblings were 17 and
14 years old).
In family 3, there were three affected males, including
two maternal cousins for whom clinical information was
available for the study (Figure 1). At the ages of 18 and
21, both cousins were diagnosed with short stature
(160.0 cm). Neither received hormone therapy. A maternal
family history of dwarfism was present. Both mothers
measured 147.3 cm. Symptoms of delayed puberty or hy-
pergonadotropic hypoganadism were not reported. Case
F3 III-7 reported speech and behavioral developmental
delays of 15–16 months. He was diagnosed with infantilerican Journal of Human Genetics 88, 718–728, June 10, 2011 721
Table 1. Main Characteristics of Symptomatic Members of Families F1 and F2
Family 1 Family 2
III-1 II-1 II-2 II-3 II-4 II-2 II-1
Gender M M M M M M M
Current age (age at death), yr 28 (34) 41 45 48 14 17
Short stature of postnatal onset yes yes yes yes yes yes yes
Facial dysmorphism yes yes yes yes yes yes yes
Premature canities yes yes yes yes yes no no
Azoospermia yes yes yes n.a. n.a. n.a. n.a.
Hormonal testing
Age at testing, yr 17 29 30 44 46 14 12.5
Testis volume—Tanner Stage n.a. T1 T2 n.a. n.a. T1 T1
Testosterone, nmol/litera 3.47 (Y) 23.6 19.8 5.7 6.6 0.29 0.11 (Y)
LH plasma levels, IU/literb 9 ([) 14 ([) 10 ([) 11 ([) 20.3 ([) 0.3 ([) 0.25 ([)
FSH plasma levels, IU/literc 71 ([) 37 ([) 36 ([) 38 ([) 48.6 ([) 2.4 4.1 ([)
AMH, pmol/literd n.a. n.a. n.a. <0.35 <0.35 n.a. 358
Inhibin B, pg/mle n.a. <15 (Y) <15 (Y) <15 (Y) <15 (Y) n.a. n.a.
IGF-1, mcg/literf n.a. n.a. n.a. n.a. n.a. 116(Y) n.a.
Partial GH insufficiencyg yes yes no n.a. n.a. yes yes
Stroke no yes yes yes yes yes no
Age at neurological onset, yr - 22 35 34 4 10 -
Moya-Moya angiopathyh no yes yes yes yes yes yes
History of hypertension no no no no no yesi no
Dilated Cardiomyopathyj yes yes no yes no no no
Right aortic arch n.a. no n.a. yes n.a. n.a. no
Early onset cataract yes no yes yes yes no no
a Normal values: 5.4–30.4 for tests performed in family 1, 0.28 5 0.01 for tests performed in family 2.
b Normal values: 1–7 for family 1, 0.17–0.19 for family 2.
c Normal values: 1.5–14 for family 1, 0.44–3.1 for family 2.
d Normal values: 15–90 for family 1, 250–1500 for family 2.
e Normal values: 80–270.
f Normal values: 230–876.
g The definition of complete and partial GH deficiency was a GH peak response of less than 3 and 10 ng/ml, respectively, after a stimulation test.
h Moyamoya angiopathy on MR Angiography or Conventional Angiography.
i No renal artery stenosis was detected on ultrasound examination.
j The definition of dilated cardiomyopathy was an association of left ventricular enlargement with reduction of left ventricular fraction shortening. A down arrow
indicates a decrease, and an up arrow indicates an increase.febrile seizures at the age of 1 and epilepsy at the age of 10.
He is hypertensive and has hypercholesterolemia, which
is present among his immediate family members. He pre-
sented with right-hemisphere transient ischaemic attacks
(TIAs), and anMR head scan demonstrated bilateral frontal
watershed infarcts. Digital subtraction angiography
showed bilateral supraclinoid internal carotid artery
(ICA) occlusion and extensive moyamoya collateral vessels
bilaterally (Figure S1). Case F3 III-2 had developmental
delays in walking, speaking, and social behavior at an early
age, was diagnosed with an enlarged heart at the age of 8,
and suffered a myocardial infarction at the age of 21 as
measured by elevated troponin levels. Subsequent cardiac722 The American Journal of Human Genetics 88, 718–728, June 10,catheterization showed significant coronary artery disease.
He was also diagnosed with hypertension. He suffered left-
hemisphere TIAs, and an MR head scan showed bilateral
watershed infarcts. Digital subtraction angiography
showed a right cervical ICA occlusion; reconstitution of
the cavernous ICA from multiple collateral vessels,
including moyamoya vessels; and in the left cervical ICA,
multiple areas of irregularity and narrowing. These findings
suggested prior occlusion with partial recanalization and
occlusion of both vertebral artery origins with reconstitu-
tion from collateral vessels (Figure S2). He also had dysmor-
phic facial features, including a narrow cranial vault, thick
eyebrows, wide nose, deeply set eyes, and low-set ears, as2011
Figure 3. Progression of the Moyamoya Angiopathy in Case F1
II-2 over 8 Years
At baseline, MRA shows a bilateral stenosis of the terminal portion
of the ICAs and the origin of ACAs and MCAs (yellow arrows).
Three years later, a progression of the arterial stenoses is visible
on MRA and punctuate ischemic lesions are detected on MRI
(red arrows). A 8 years follow-up examination reveals a progression
of the angiopathy with left ICA occlusion (green arrow) and larger
ischemic lesions.well as significant graying (over 75%) of the hair at the age
of 26.
Cosegregation of an Xq28 Deletion in Affected
Members of Family F1
The segregation of the disease in family F1 strongly sug-
gested an X-linked recessive pattern of inheritance. To
confirm this hypothesis, we conducted a genetic-linkage
analysis in this family by using a panel of microsatellite
markers spanning the X chromosome. A maximum multi-
point point LOD score of 2.1 (maximum theoretical LOD
score in family F1) was obtained at four closely linked
markers, DXS8106, DXS8045, DXS1193, and DXS8061,
mapping on Xq27–q28. Haplotype analysis mapped the
gene as being distal to DXS984 (centromeric boundary)
as the result of a recombination event in the affected indi-
vidual III-1 (Figure S3). None of the telomeric markers,
down to the telomere, detected any recombinant event.
The physical size of the linked region has been estimated
to be close to 15.5 Mb.
Because the pleiotropism of the clinical manifestations
observed in family F1was possibly consistentwith a contig-
uous gene-deletion syndrome, we used an Affymetrix SNP
6.0 array to screen for putative loss of genetic material
within the linked region on chromosome X. We analyzed
three members, including the mother (F1 I-2) and two of
her affected sons (F1 II-3 and F1 II-4).
Ten consecutive copy-number probes detected putative
null alleles in the two affected sons, and hemizygosity
for these markers was observed in the mother (Table S3).
These consecutive probes spanned a 46.3 Mb interval
bracketed by CN_923665 and CN_923676 copy-number
probes (Table S3 and Figure 4C). Amplification of four
STS markers, including ECD13623, ECD07678,
ECD07752, and ECD15347, within this interval failed inThe Ameall affected males of family F1, confirming the existence
of a deletion within the linked interval. Flanking STS
markers ECD21451 (cen) and ECD20005 (tel) were success-
fully amplified. We then used walking PCR with additional
STS markers in combination with long-range PCR and
sequencing to identify the centromeric and telomeric
breakpoints. In brief, for all affected individuals we ampli-
fied a 3416 bp fragment that was absent in control individ-
uals and present in the heterozygous state in the obligate
female carriers. The sequencing of this PCR product re-
vealed that the deletion size was 41007 bp long. Interest-
ingly, a 32 bp insertion was detected at the breakpoint
junction. This insert corresponded to a small part of the
first intron of MTCP1/MTCP1NB.
This deletion interrupted two genes, FUNDC2 and
BRCC3, and deleted entirelyMTCP1/MTCP1NB. The break-
point within FUNDC2 occurred within exon 2, and the
breakpoint in BRCC3 occurred within intron 3.
Altogether, these data established the existence of a40 kb
Xq28 deletion that cosegegated with the affected pheno-
type in family F1.
Detection of Additional Xq28 Deletions in Families F2
and F3
Family F2 includes two affected brothers (F2 II-1 and F2
II-2) whose phenotypes were strikingly similar to the one
observed in family F1. The blood of both brothers and their
two parents was sampled. We failed to amplify the first
exon of MTCP1/MTCP1NB or exons 1–3 of BRCC3 in
proband F2 II-2 and his brother F2 II-1, strongly suggesting
the existence of a genomic deletion. Walking PCR, long-
range PCR, and sequencing identified a 5295 bp deletion
in these two affected brothers. Their mother was heterozy-
gous for this deletion. The deleted fragment removed
691 bp of intron 1 and exon 1 ofMTCP1/MTCP1NB, exons
1–3 of BRCC3, and 1866 bp of intron 3 of BRCC3.
Family F3 includes three affected males. The blood of
two of them (F3 III-2, F3 III-7) as well as that of the mother
of F3 III-7 (F3 II-4) has been sampled. A 4218 bp deletion
removing 197 bp of exon 1 of MTCP1/MTCP1NB, exons
1–3 of BRCC3, and 1860 bp of intron 3 of BRCC3 has
been identified in both cousins and the carrier mother F3
II-4 .
The Critical Region of Overlap between F1, F2,
and F3 Deletions Includes MTCP1/MTCP1NB Exon 1
and the First Three Exons of BRCC3
The three deletions observed in families F1, F2, and F3
overlapped over an interval of 3362 bp, which is thus
defined as a new critical interval that includes MTCP1/
MTCP1NB exon 1 and the first three exons of BRCC3.
FUNDC2 is located outside of this region, strongly suggest-
ing that it is not involved in the disease.
MTCP1 was until recently annotated as a single locus
expressing alternatively spliced transcripts; it is now
annotated as two genes, MTCP1 and MTCP1NB, sharing
exon 1 and encoding two distinct proteins, p13MTCP1rican Journal of Human Genetics 88, 718–728, June 10, 2011 723
Figure 4. Xq28 Deletions in Families
F1–F3
(F1) The deletion in family F1 begins after
the 153,914,898th nucleotide of chromo-
some X (build 36.3) within the second
exon of FUNDC2. It removes the remain-
ing part of FUNDC2, MTCP1/MTCP1NB,
and three exons of BRCC3. A fragment of
32 bp is inserted at the breakpoint junc-
tion.
(F2) The deletion identified in family F2
begins after the 153,951,471th nucleotide
within intron 1 of MTCP1/MTCP1NB. It
removes exon 1 ofMTCP1 and three exons
and part of intron 3 of BRCC3.
(F2) The deletion identified in family F3
begins after the 153,952,544th nucleotide,
within exon 1 of MTCP1/MTCP1NB. It re-
moves part of exon 1 of MTCP1 and three
exons and part of intron 3 of BRCC3.
(Lower panel) Schematic view of the
region involved in the deletion. Approxi-
mate positions of Affymetrix SNP 6.0 array
probes and STS markers used for deletion
mapping are shown. The copy-number
probes flanking the deletion in family F1
are boxed. The STS markers showing the
null alleles are represented as empty bars;
the filled bars indicate that the sequence
is not deleted. The dashed black lines
show the deleted region in families F1–
F3. Black arrows indicate the breakpoints.
The genes interrupted by the deletion are
represented as vertical, differently colored
bars, and arrows indicate their transcrip-
tional direction. The 3362 bp critical
interval is represended by a dashed line,
and the exons lying within this region
are denoted by empty bars.and p8MTCP1NB . The protein p13MTCP1 is not detected in
normal tissues but is restricted to a rare form of mature-T-
cell-proliferation leukemia. P8MTCP1NB encodes a mito-
chondrial 8 kDa protein of unknown function. BRCC3
encodes a 36 kDa ubiquitous deubiquitinating enzyme.
MTCP1 and BRCC3 Screening in Patients with
Nonsyndromic Familial Moyamoya Disease
The screening of the coding regions and intron-exon
boundaries of BRCC3, MTCP1, and MTCP1NB in the
probands of the three pure MMD-unrelated F4–F6 families
did not detect any deleterious mutation.724 The American Journal of Human Genetics 88, 718–728, June 10, 2011p8MTCP1NB and BRCC3 Analysis
in Patient Lymphoblastoid Cell
Lines and in Human Vascular
Tissues
Immunoblot analysis of EBV lym-
phoblastoid cell lines from affected
individuals F1 II-2 and F2 II-2 did
not detect BRCC3 or p8MTCP1NB,
whereas these proteins were readily
detected in healthy control EBV cell
lysates (Figure S5).p8MTCP1NB and BRCC3 were also readily detectable in
HUVEC endothelial cells as well as in arterial and venous
lysates from normal human individuals (Figure S4).
Morpholino-Mediated Knockdown of brcc3 Leads
to Defective Angiogenesis in Zebrafish
We decided to further examine the function of the genes
inactivated by the deletions in families F1–F3 by using
the zebrafish. The region syntenic to the portion of the
genome removed by the overlapping deletion of these
families is found on zebrafish chromosome 21. The human
and zebrafish syntenic regions share similar organization;
Figure 5. Zebrafish Orthologs of Moyamoya Candidate Genes
(A) Schematic drawing depicting the moyamoya deletion critical
region in the human genome and comparing it to the syntenic
region of the zebrafish genome. An untranslated exon (cyan) is
alternatively spliced (dashed lines) into two transcripts encoding
the unrelated MTCP1 (green) and MTCP1NB (blue) proteins. The
mtcp1nb (blue) and brcc3 (black) loci are conserved in zebrafish,
but mtcp1 is absent.
(B)The whole-mount in situ hybridization of a 24 hpf zebrafish
embryo probed for brcc3, showing lower level ubiquitous expres-
sion with somewhat higher expression in the head and around
the trunk axial vessels (arrows). The scale bar represents 200 mm.there is a small intergenic GC island located between the
mtcp1nb and brcc3 loci, which are transcribed in opposite
directions (Figure 5A). Amtcp1 homolog is not found in ze-
brafish.Mtcp1 homologs are present in both mammals and
sauropsids but are not detected in amphibians, suggesting
that Mtcp1 arose in the last common tetrapod ancestor
shared by mammals and sauropsids (Figure S6). In situ
hybridization of 24 hr postfertilization (hpf) zebrafish
embryos reveals low-level ubiquitous expression of brcc3
ortholog with somewhat higher levels of expression in
the head and in the ventral trunk adjacent to developing
vessels (Figure 5B). Expression ofmtcp1nb is not detectable
by in situ hybridization in 24 hpf embryos (data not
shown).
The role of brcc3 and mtcp1nb in vascular development
was analyzed by morpholino-mediated knockdown in
Tg(fli1-eGFP)y1 transgenic zebrafish embryos, which permit
easy visualization of blood vessels by fluorescence micros-
copy because of eGFP expression within endothelial cells
of the transparent animal15 (Figure 6). Injection of mor-
pholinos targeting brcc3 inhibits angiogenesis of trunk
intersegmental vessels (Figure 6C). This defect is amelio-
rated by coinjection of wild-type brcc3 mRNA (Figures 6D
and 6E), suggesting that defective angiogenesis in brcc3
morpholino-injected animals is due to a specific functional
requirement for this gene. As noted above, brcc3 shows
a low level of ubiquitous expression, but increased expres-
sion is noted in the vicinity of the developing axial blood
vessels from which the intersegmental vessels sprout andThe Amegrow. To determine whether the defects in brcc3 morpho-
lino-injected animals reflect a cell-autonomous require-
ment for brcc3 function within endothelial cells, we gener-
ated flk1-mCherry-2A-brcc3 and flk1-mCherry constructs for
endothelium-specific expression, driven by the flk1
promoter, of either brcc3 plus mCherry or mCherry alone.
Injection of these constructs into zebrafish embryos results
in mosaic endothelial expression of their respective
transgenes (Figures 6F–6I). Expression of brcc3 in ISVs of
injected Tg(fli1-eGFP)y1 animals is sufficient to rescue
angiogenic sprouting and growth (arrows); in comparison,
in transgenic flk1-mCherry-expressing endothelial cells
(arrowheads), no rescue was observed (Figures 6F–6J).
Unlike brcc3 morpholino-injected animals, mtcp1nb mor-
pholino-injected animals showed no vascular phenotype
at either 24 hpf or 48 hpf (data not shown). These results
indicate that brcc3 ortholog function is required cell-
autonomously within the endothelium for angiogenesis.Discussion
We report herein on three unrelated families affected by
a disorder characterized by the association of a moyamoya
angiopathy, short stature, and a stereotyped facial dysmor-
phism. In addition, other symptoms included a hypergona-
dotropic hypogonadism (7/9 patients), hypertension (3/9
patients), a dilated cardiomyopathy (3/9 patients), prema-
ture coronary heart disease (1/9 patients), premature hair
graying (6/9 patients), and early bilateral acquired cataract
(4/9 patients). In these three families, we identified three
overlapping Xq28 deletions cosegregating with the
affected phenotype. The critical interval includes exon 1
of MTCP1/MTCP1NB and exons 1–3 of BRCC3. This dele-
tion leads to a complete loss of BRCC3 and MTCP1NB
(the sole MTCP protein expressed in normal tissues) in
affected patients. In order to investigate the in vivo conse-
quences of the loss of each of these two proteins, we con-
ducted morpholino knockdown experiments for both
genes in zebrafish. Knockdown of mtcp1nb did not lead
to any vascular phenotype at either 24 hpf or 48 hpf,
whereas injection of morpholinos targeting brcc3 lead to
defective angiogenesis, which was rescued by endothelial
expression of brcc3.
The defective angiogenesis observed in brcc3 morphant
zebrafish and the endothelial-specific brcc3 rescue of these
defects strongly suggest that this protein plays an impor-
tant role in vascular physiology and may therefore be
involved in the moyamoya angiopathy of these patients.
BRCC3 is a ubiquitously expressed K63-specific deubiqui-
nating (DUB) enzyme containing a JAMM (JAB1/MPN/
Mov34 metalloenzyme) domain.21–24 It is a member of
two protein complexes, the nuclear BRCA1/Rap80/
Abraxas/Merit40/BRCC45 DNA repair complex and the
cytoplasmic BRISC complex.25 After cell irradiation,
BRCC3 is readily detected at DNA double-strand breaks,
where it interacts with abraxas and is thought to berican Journal of Human Genetics 88, 718–728, June 10, 2011 725
Figure 6. Loss of brcc3 Function in the Endothelium Results in Defective Angiogenesis
(A) Drawing of 24 hpf zebrafish embryo (adapted from Kimmel et al.37). The region shown in subsequent panels is highlighted in blue.
(B–D) Confocal imaging of intersegmental vessels (ISVs) in 24 hpf Tg(flk1a-eGFP) transgenic zebrafish embryos injected with either
control morpholino (B), brcc3 morpholino (C), or brcc3 morpholino plus brcc3 mRNA (D).
(E) Quantitation of the percentage of ISVs that sprout and grow at least half-way up the trunk (to the horizontal myoseptum) in
morpholino- and mRNA-injected animals.
(F–I) Confocal imaging of ISVs in 24 hpf Tg(flk1a-eGFP) transgenic zebrafish embryos injected with either flk1-mCherry-2A-brcc3 (F and
G) or flk1a-mCherry (H and I) transgene DNA, showing EGFP-positive vessels (F and H) and mCherry-positive transgene-expressing cells
(G and I).
(J) Quantitation of the percentage of ISVs that sprout and grow at least half-way up the trunk (to the horizontal myoseptum) in
flk1a-mCherry-2A-brcc3 or flk1a-mCherry transgene-injected animals. For the quantitative data in panels (E) and (J), ten ISVs from
each of 12 different injected embryos were scored for each control and experimental condition. Error bars show the standard error of
the mean for these data. Scale bars represent 25 mm (B–D) and 25 mm (F–I).a positive regulator of BRCA1 E3 ligase activity. It is impli-
cated in G2 checkpoint and viability response through its
DUB activity. How an alteration of DNA repair could
possibly lead to moyamoya angiopathy would be entirely
speculative at this point. However, several lines of evidence
suggest a possible link between genomic maintenance and
moyamoya. Irradiation of the neck is one of the most
frequent environmental causes of moyamoya, and the
clinical, radiological, and histological features of irradia-
tion-induced cerebral vasculopathy and those of MMD
are strikingly similar.5 In addition, moyamoya angiopathy
is a frequent complication of MOPDII (MIM 210720, Ma-
jewski Osteodysplastic Primordial dwarfism) and Seckel
syndrome (MIM 210600, 606744, 613676, 608664) which
are recessive disorders caused by mutations of pericentrin,
a protein involved in DNA-damage signaling.26–28 Other
clinical features, such as early acquired cataract and prema-
ture hair graying, encountered in these patients are also
present in several disorders caused by mutations in DNA
repair genes.726 The American Journal of Human Genetics 88, 718–728, June 10,BRCC3 is also a member of the BRISC complex (BRCC36
Isopeptidase Complex), a cytoplasmic complex containing
BRCC3, BRCC45, MERIT40, and ABRO1, a complex whose
function was until recently totally unknown.25,29,30
Recent data suggest that ABRO1 and the BRISC complex
might have a cardioprotective function.31 Indeed, ABRO1
is strongly expressed in cardiomyocytes and is upregulated
in myocardial infarction. Its induction is associated with
a K63-linked deubiquitination of cardiomyocyte proteins
associated with a cardio-protective effect. An exciting
hypothesis is that loss of the integrity of the BRISC
complex could lead to the cardiomyopathy and premature
coronary heart disease detected in several of our patients.
In addition to moyamoya angiopathy, all patients have
a short stature (and most have partial GH deficiency).
Seven out of nine patients showed a hypergonadotropic
hypogonadism, suggesting a preferential dysfunction of
Sertoli cells. BRCC45 (also called BRE) is mostly expressed
in the testis; there is a strong mRNA signal in germ cells
and Sertoli cells.32 Because BRCC45 is a member of both2011
BRCC3 complexes, either of these two complexes could
also be involved in this endocrine phenotype. Interest-
ingly, hypergonadotropic hypogonadism and infertility
are important clinical features encountered in several chro-
mosome-breakage and -instability syndromes, including
Fanconi anemia.33
Because both MTCP1/MTCP1NB and BRCC3 are inter-
rupted in all three families, a role for MTCP1/MTCP1NB
loss in the disease phenotype cannot be ruled out at this
point. MTCP1, also called c6.1B, was initially identified
because of its involvement in the t(X;14)(q28;q11) translo-
cation, which is associated with a rare subset of T cell pro-
lymphocytic leukemia, involving proliferation of mature
T cells.34–36 It leads to two types of transcripts, MTCP1
and MTCP1NB, with two distinct open reading frames.
The longest transcript encodes p13MTCP1, a protein that
is not found in any normal tissue but only in Tcell prolym-
phocytic leukemic cells, in which the t(X;14) translocation
event activates a cryptic promoter sequence withinMTCP1
intron 1. p8MTCP1NB encodes a mitochondrial 8 kDa
protein whose function is unknown and which is detected
in various normal tissues, including arteries and veins, and
is overexpressed in mature T cell leukemia cells. This
unusually small 68 amino acid protein is expressed in the
mitochondria. However, at present we have no idea as to
the putative pathophysiological links between its loss
and the phenotype, or part of the phenotype, reported
herein.
In summary, we report herein on a novel X-linked
syndromic moyamoya disorder whose investigation leads
to the identification of a deletion removing two genes
with a previously unsuspected role in vessel physiology.
Several lines of evidence strongly suggest that one of these
two genes, BRCC3, might play an important role in angio-
genesis and vessel maintenance.Supplemental Data
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